BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 34172531)

  • 1. Current Development of Glioblastoma Therapeutic Agents.
    Wang Z; Peet NP; Zhang P; Jiang Y; Rong L
    Mol Cancer Ther; 2021 Sep; 20(9):1521-1532. PubMed ID: 34172531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain/brain tumor barriers for glioblastoma treatment.
    Wang D; Wang C; Wang L; Chen Y
    Drug Deliv; 2019 Dec; 26(1):551-565. PubMed ID: 31928355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in targeted drug delivery for the treatment of glioblastoma.
    Mao M; Wu Y; He Q
    Nanoscale; 2024 May; 16(18):8689-8707. PubMed ID: 38606460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular pathways and potential therapeutic targets in glioblastoma multiforme.
    Wardak Z; Choe KS
    Expert Rev Anticancer Ther; 2013 Nov; 13(11):1307-18. PubMed ID: 24168050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current Challenges and Opportunities in Treating Glioblastoma.
    Shergalis A; Bankhead A; Luesakul U; Muangsin N; Neamati N
    Pharmacol Rev; 2018 Jul; 70(3):412-445. PubMed ID: 29669750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug Repurposing for Glioblastoma and Current Advances in Drug Delivery-A Comprehensive Review of the Literature.
    Alomari S; Zhang I; Hernandez A; Kraft CY; Raj D; Kedda J; Tyler B
    Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temporary blood-brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma.
    Dréan A; Lemaire N; Bouchoux G; Goldwirt L; Canney M; Goli L; Bouzidi A; Schmitt C; Guehennec J; Verreault M; Sanson M; Delattre JY; Mokhtari K; Sottilini F; Carpentier A; Idbaih A
    J Neurooncol; 2019 Aug; 144(1):33-41. PubMed ID: 31197598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. STAT3 as a Therapeutic Target for Glioblastoma.
    Liu Y; Li C; Lin J
    Anticancer Agents Med Chem; 2010 Sep; 10(7):512-9. PubMed ID: 20879983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug delivery approaches for the treatment of glioblastoma multiforme.
    Fakhoury M
    Artif Cells Nanomed Biotechnol; 2016 Sep; 44(6):1365-73. PubMed ID: 26046399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Targets and Nanoparticulate Systems Designed for the Improved Therapeutic Intervention in Glioblastoma Multiforme.
    Akhter MH; Rizwanullah M; Ahmad J; Amin S; Ahmad MZ; Minhaj MA; Mujtaba MA; Ali J
    Drug Res (Stuttg); 2021 Mar; 71(3):122-137. PubMed ID: 33167048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent Advances on Glioblastoma Multiforme and Nano-drug Carriers: A Review.
    Liao W; Fan S; Zheng Y; Liao S; Xiong Y; Li Y; Liu J
    Curr Med Chem; 2019; 26(31):5862-5874. PubMed ID: 29768997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets.
    Mao H; Lebrun DG; Yang J; Zhu VF; Li M
    Cancer Invest; 2012 Jan; 30(1):48-56. PubMed ID: 22236189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SUMOylation in Glioblastoma: A Novel Therapeutic Target.
    Fox BM; Janssen A; Estevez-Ordonez D; Gessler F; Vicario N; Chagoya G; Elsayed G; Sotoudeh H; Stetler W; Friedman GK; Bernstock JD
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 30991648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of novel small-molecule inhibitors of glioblastoma cell growth and invasion by high-throughput screening.
    Wang L; Zhao H; Cui K; Yao L; Ren M; Hao A; Smollen P; Nie F; Jin G; Liu Q; Wong ST
    Biosci Trends; 2012 Aug; 6(4):192-200. PubMed ID: 23006966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotypic Screening of Chemical Libraries Enriched by Molecular Docking to Multiple Targets Selected from Glioblastoma Genomic Data.
    Xu D; Zhou D; Bum-Erdene K; Bailey BJ; Sishtla K; Liu S; Wan J; Aryal UK; Lee JA; Wells CD; Fishel ML; Corson TW; Pollok KE; Meroueh SO
    ACS Chem Biol; 2020 Jun; 15(6):1424-1444. PubMed ID: 32243127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
    van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
    Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Jak2 small molecule inhibitor, G6, reduces the tumorigenic potential of T98G glioblastoma cells in vitro and in vivo.
    Baskin R; Park SO; Keserű GM; Bisht KS; Wamsley HL; Sayeski PP
    PLoS One; 2014; 9(8):e105568. PubMed ID: 25162558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular neuro-oncology and the challenge of the blood-brain barrier.
    Aiken R
    Semin Oncol; 2014 Aug; 41(4):438-445. PubMed ID: 25173137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel delivery strategies for glioblastoma.
    Zhou J; Atsina KB; Himes BT; Strohbehn GW; Saltzman WM
    Cancer J; 2012; 18(1):89-99. PubMed ID: 22290262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor.
    Costa B; Bendinelli S; Gabelloni P; Da Pozzo E; Daniele S; Scatena F; Vanacore R; Campiglia P; Bertamino A; Gomez-Monterrey I; Sorriento D; Del Giudice C; Iaccarino G; Novellino E; Martini C
    PLoS One; 2013; 8(8):e72281. PubMed ID: 23977270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.